Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.
about
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsCysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationA multigene array for measurable residual disease detection in AML patients undergoing SCTMinimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.Relapse assessment following allogeneic SCT in patients with MDS and AML.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cePeripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation.The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
P2860
Q28073464-910BF6CD-5210-442A-AEBD-FBF55B32140CQ33829373-ED77CC65-75A8-4E0E-9AA2-F93E8402E13BQ34861985-62A4DFB2-0B1D-4163-9C3E-6C00E6842BF6Q35582360-B98D041A-4E23-4904-99CB-E0B7B4E05A79Q37258220-D5672CA9-F66D-43CC-ABEC-A16E88E675C2Q38199623-00C00F29-2F47-4289-A8F8-8E20DB433002Q38212956-4A5EF5AB-DD31-4EBA-892E-87521EA0D3C0Q38665455-170ECE8F-B4AC-4745-88B4-0832F6B53522Q38863489-EEEC7A27-953E-4A64-990E-345DF1548C5EQ38947873-0DD13122-2823-41ED-ACD1-7E3909FFCB63Q39329093-86D8A930-89D7-453F-82FF-8A7708939676Q39683026-6A51942C-E860-4D67-8E28-774F13239816Q40296180-EA3E2E4D-3657-4658-A607-69C67D44BF7BQ41717987-92B24A4E-3C03-4874-85FE-03B896256D36Q41948692-02ED2425-AA54-4A2F-B994-68D4E42D3526Q42968779-5067A1AD-272F-4805-977A-BEFB1056DF9BQ44140205-C4DBBD10-26EA-48EA-AFA1-57B9385E1545Q45886072-CE08805D-6303-4CA2-9CD3-092EF36A7FCEQ49710183-4BC68698-12C2-4E50-96C4-7EC17AF4C096Q53011046-310E1F13-A81D-4E5F-93A8-3D9F65D7F0E2
P2860
Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Combined use of WT1 and flow c ...... without affecting specificity.
@en
Combined use of WT1 and flow c ...... without affecting specificity.
@nl
type
label
Combined use of WT1 and flow c ...... without affecting specificity.
@en
Combined use of WT1 and flow c ...... without affecting specificity.
@nl
prefLabel
Combined use of WT1 and flow c ...... without affecting specificity.
@en
Combined use of WT1 and flow c ...... without affecting specificity.
@nl
P2093
P2860
P1433
P1476
Combined use of WT1 and flow c ...... without affecting specificity.
@en
P2093
Chen-hua Yan
Dai-hong Liu
Kai-yan Liu
Lan-ping Xu
Xiao-jun Huang
Xiao-su Zhao
Ya-zhen Qin
Yan-rong Liu
P2860
P304
P356
10.1007/S00277-013-1733-1
P577
2013-05-17T00:00:00Z